EUSA Pharma launches phase III COVID-19 study for siltuximab
Study will enrol hospitalised COVID-19 patients with serious viral acute respiratory distress syndrome
Read More
Tag: EUSA Pharma
EUSA Pharma bags US approval for COVID-19 trial
Siltuximab is a monoclonal antibody that directly neutralises interleukin (IL)-6, an inflammatory cytokine
Read More
Positive early data from siltuximab COVID-19 trial
One-third (33%) of patients experienced a clinical improvement with a reduced need for oxygen support
Read More
NICE backs Qarziba for children with high-risk neuroblastoma
NHS funding for EUSA’s Pharma’s Qarziba has been approved to treat children with high-risk neuroblastoma.
Read More
Long-term benefit of Qarziba uncertain, says NICE
The National Institute for Health and Care Excellence has ruled against the provision of NHS funding for EUSA Pharma’s neuroblastoma treatment Qarziba.
Read More
EU approves first immunotherapy for neuroblastoma
EU regulators have issued a green light for the first immunotherapy for high-risk neuroblastoma, offering thousands of children affected by the rare and devastating form of cancer a new treatment option.
Read More
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
